QAW039 150 mg
CQAW039A2315
Phase 3 small_molecule terminated
Quick answer
QAW039 150 mg for Asthma is a Phase 3 program (small_molecule) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- Asthma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated